Potassium loss associated with hydrochlorothiazide versus chlorthalidone

Area of Science:

• Nephrology
• Pharmacology
• Internal Medicine

Background:

• Diuretics are commonly prescribed for hypertension and edema.
• Hypokalemia is a potential adverse effect of thiazide diuretics.
• Understanding the comparative risk of hypokalemia is crucial for patient safety.

Purpose of the Study:

• To compare the incidence of clinically significant hypokalemia between chlorthalidone (CTLD) and hydrochlorothiazide (HCTZ).
• To investigate the influence of diuretic duration of action on serum potassium levels.

Main Methods:

• Retrospective chart review of patients receiving CTLD or HCTZ.
• Analysis of hypokalemia incidence, defined as serum potassium ≤ 3.0 mEq/liter.
• Statistical comparison using the Fisher exact probability test.

Main Results:

• Hypokalemia occurred in 13.8% of patients on once-daily CTLD.
• No hypokalemia was observed in patients on twice-daily HCDL or once-daily HCTZ.
• A significant difference in hypokalemia incidence was found between once-daily CTLD and once-daily HCTZ groups.

Conclusions:

• Chlorthalidone (CTLD) is associated with a higher incidence and degree of hypokalemia compared to hydrochlorothiazide (HCTZ).
• The longer duration of action of CTLD contributes to increased risk of hypokalemia.
• Dosing frequency and diuretic's pharmacokinetics influence electrolyte balance.